云南高校图书馆联盟文献共享服务平台- ADJUVANT

ADJUVANT: 作品数：496被引量：1918H指数：20; 导出分析报告; 相关领域：医药卫生更多>>; 相关作者：郭虹陈观今郑焕钦许小琴饶平凡更多>>; 相关机构：中山大学吉林大学第二军医大学福州大学更多>>; 相关期刊：更多>>; 相关基金：国家自然科学基金国家重点基础研究发展计划中国博士后科学基金高等学校学科创新引智计划更多>>

Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer被引量：1: 《World Journal of Clinical Oncology》2021年第10期912-925,共14页Miguel J Sotelo Jose Luis García Cesar Torres-Mattos Héctor Milián Carlos Carracedo María Angeles González-Ruiz Xabier Mielgo-Rubio Juan Carlos Trujillo-Reyes Felipe Couñago; Patients with early-stage non-small-cell lung cancer(NSCLC)are candidates for curative surgery;however,despite multiple advances in lung cancer management,recurrence rates remain high.Adjuvant chemotherapy has been de...; 关键词：Non-small-cell lung cancer Early stage Epidermal growth factor receptormutated Epidermal growth factor receptor-mutated-tyrosine kinase inhibitor ADJUVANT NEOADJUVANT

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer被引量：1: 《World Journal of Clinical Oncology》2019年第5期201-212,共12页Trishala Meghal Vishangi Dave Horace Tang Vivek Kumar Yiqing Xu; BACKGROUND Adjuvant chemotherapy using intraperitoneal(IP)treatment has demonstrated survival benefit over intravenous(IV)therapy alone in patients treated with upfront debulking surgery for advanced stage ovarian can...; 关键词：OVARIAN cancer INTRAPERITONEAL chemotherapy Community setting Safety TOLERABILITY Outcome

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key被引量：4: 《World Journal of Clinical Oncology》2017年第6期437-446,共10页Connie Rabanal Rossana Ruiz Silvia Neciosup Henry Gomez; Triple negative breast cancer(TNBC) accounts for 15%-20% of all breast cancer, and is still defined as what it is not. Currently, TNBC is the only type of breast cancer for which there are no approved targeted therapi...; 关键词：METRONOMIC chemotherapy TRIPLE negative BREAST cancer NEOADJUVANT ADJUVANT Maintenance

Evolving role of Sorafenib in the management of hepatocellular carcinoma被引量：6: 《World Journal of Clinical Oncology》2017年第3期203-213,共11页Ioannis A Ziogas Georgios Tsoulfas; Hepatocellular carcinoma(HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality.Although there is a broad spectrum of treatment options to choose from,only a few patien...; 关键词：SORAFENIB Hepatocellular carcinoma LIVER NEOPLASM Multikinase inhibitor Targeted THERAPY Tumor angiogenesis Signaling pathways ADJUVANT THERAPY LIVER cancer LIVER transplantation LIVER RESECTION

Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer: 《World Journal of Clinical Oncology》2017年第1期54-66,共13页Tia Harmon Adriana Harbuzariu Viola Lanier Crystal C Lipsey Ward Kirlin Lily Yang Ruben R Gonzalez-Perez; The National Cancer Institute at the National Institutes of Health(1R41 CA183399-01A1 to Ruben R Gonzalez-Perez;5U54 CA118638,S21 MD000101,5G12 MD0076021,G12 RR026250-03,NIH RR03034 and 1C06 RR18386 to Morehouse School of Medicine);the National Institute of General Medical Sciences,Research Initiative for Scientific Enhancement Program(RISE 5R25 GM058268 to Tia Harmon);the Congressionally Directed Medical Research Programs-Department of Defense(CDMRP DOD W81XWH-13-1-0382 to Ruben R Gonzalez-Perez); AIM To develop a leptin peptide receptor antagonist linked to nanoparticles and determine its effect on viability of breast cancer cells.METHODS The leptin antagonist, LPrA2, was coupled via EDAC [1-Ethyl-3-(3-dimethy...; 关键词：TRIPLE negative BREAST cancer OBESITY LEPTIN LEPTIN peptide receptor ANTAGONIST 2 Iron oxide nanoparticles Chemotherapy ADJUVANT

Adjuvant chemotherapy for rectal cancer:Is it needed?: 《World Journal of Clinical Oncology》2015年第6期225-236,共12页Kristijonas Milinis Michael Thornton Amir Montazeri Paul S Rooney; Adjuvant chemotherapy has become a standard treatment of advanced rectal cancer in the West. The benefits of adjuvant chemotherapy after surgery alone have been well established. However,controversy surrounds the use ...; 关键词：RECTAL CANCER ADJUVANT CHEMOTHERAPY

Advances in adjuvant systemic therapy for non-small-cell lung cancer被引量：7: 《World Journal of Clinical Oncology》2014年第4期633-645,共13页David Leong Rajat Rai Brandon Nguyen Andrew Lee Desmond Yip; Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Da...; 关键词：CARCINOMA Non-small-cell LUNG CHEMOTHERAPY ADJUVANT RADIOTHERAPY Biological therapy BIOMARKER

Apoptosis block as a barrier to effective therapy in non small cell lung cancer被引量：7: 《World Journal of Clinical Oncology》2014年第4期588-594,共7页Ian Paul J Mark Jones; Lung cancer, is the most common cause of cancer death in men and second only to breast cancer in women. Currently, the first line therapy of choice is platinumbased combination chemotherapy. A therapeutic plateau has ...; 关键词：APOPTOSIS Lung cancer ADJUVANT THERAPY MITOCHONDRIA BAX BAK BCL2

Pathogenesis, prevention, diagnosis and treatment of breast cancer被引量：17: 《World Journal of Clinical Oncology》2014年第3期283-298,共16页Rupen Shah Kelly Rosso S David Nathanson; Breast cancer is the most common cancer affecting women worldwide. Prediction models stratify a woman's risk for developing cancer and can guide screening recommendations based on the presence of known and quantifiabl...; 关键词：BREAST cancer Risk factors Screening STAGING SURGICAL management ADJUVANT therapy

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen被引量：5: 《World Journal of Clinical Oncology》2014年第3期374-381,共8页Christos Markopoulos Stylianos Kykalos Dimitrios Mantas; Biotransformation of tamoxifen to the potent antiestrogen endoxifen is performed by cytochrome P450(CYP) enzymes, in particular the CYP2D6 isoform. CYP2D6*4 is one of the most frequent alleles associated with loss of ...; 关键词：CYP2D6 TAMOXIFEN BREAST CANCER ADJUVANT treatment

ADJUVANT